The United States has long set the pace in medical science. Its public research agencies — from the National Institutes of Health (NIH) to the Center for the Biomedical Advanced Research and Development Authority (BARDA) — have underpinned decades of vaccine and drug innovation. But with broad reductions in government-backed medical science funding under the Trump administration, including an about-face on mRNA vaccine research, that leadership role looks less certain.
Scientists warn the decision to slash funding for more than 20 mRNA vaccine projects risks stalling promising work just as mRNA research was beginning to expand into flu, RSV and cancer. Investors, meanwhile, are weighing what happens to an industry suddenly deprived of hundreds of millions in early-stage support. What seems clear is that others are ready to fill the gap.
Opportunity in the vacuum
Best positioned to step in are Europe and China, which have both invested heavily in biotech infrastructure over the past decade. The EU has long cultivated cross-border research programs, and with strong pharma hubs in Germany, Switzerland and the UK, it has the capacity to accelerate mRNA pipelines that the US has walked away from.
China has been explicit about making biotech a strategic priority. Significant state funding, a large patient base for trials and fast-tracked regulatory pathways give it the ability to scale quickly. Canada has also indicated willingness to host displaced projects, while Singapore continues to court biotech investment with grants and clinical trial capacity that punch above its size.
In short, the innovation map is shifting. Where once early-stage vaccine breakthroughs were almost synonymous with Boston or San Francisco, they could increasingly emerge from Europe, Asia and smaller but ambitious hubs.
What it means for Australia
Australia is not immune to these dynamics. While it lacks the scale of Europe or China, it has already demonstrated strength in infectious disease research through institutions like the Doherty Institute, CSIRO and WEHI. If the US creates uncertainty, Australia has an opportunity to present itself as a reliable partner for international collaboration.
There is also the possibility of a scientific “brain gain.” Talented researchers unsettled by US policy changes may look abroad, and Australia’s combination of quality research centres, established trial networks and growing biotech capital markets could make it an attractive option.
For ASX-listed biotechs, the picture is nuanced. Companies focused narrowly on mRNA may face more investor caution, as US funding decisions filter through to global capital flows. But those working on adjacent platforms — from diagnostics to alternative vaccine technologies — could find new openings as the global balance of research shifts.
Investor caution takes hold
Markets have already signalled unease. Moderna shares have been volatile, and venture funds are reportedly pausing before backing new mRNA ventures. The hesitation reflects more than just one technology: it shows how closely investor confidence is tied to predictable public support.
For Australian investors, the message is twofold. First, US policy decisions can ripple quickly through global biotech valuations. Second, diversifying into companies with broader vaccine or immunotherapy pipelines may help navigate the uncertainty.
A multipolar biotech landscape
The bigger picture is that biotech innovation is unlikely to slow — but it may be redistributed. Instead of breakthroughs clustering around US institutions, future advances could emerge from Europe, Asia or smaller regional hubs. That could mean more cross-border partnerships, more competition for talent and, potentially, a more resilient global research ecosystem.
For Australia, this environment holds risks but also genuine upside. By building on its existing strengths and positioning itself as a stable research partner, it can play a more prominent role in the next phase of vaccine innovation.
When the US steps back, others will step forward. The question for the industry — and for investors — is which countries are ready to lead, and how quickly they can turn today’s uncertainty into tomorrow’s breakthroughs.